Director – Investigational Drug Section
START Center for Cancer Research
Director – Investigational Drug Section
START Center for Cancer Research
Phase 1 cancer trials with genomic profiling
The START Center for Cancer Research (“START”) is the world’s largest early phase site network, fully dedicated to oncology clinical research. To date, over 45 therapies conducted at START locations have obtained FDA/EMA approval.
The START Center for Cancer Research is seeking a Director, Investigational Drug Section who is responsible for overseeing all components of IDS operations at the assigned site. Additionally, the director should fulfill all existing clinical pharmacist job duties. This includes all facets of medication order verification, dispensing and documentation process for investigational drugs, conventional chemotherapy and supportive care medications provided by the IDS. The pharmacist may be involved in the provision of pharmaceutical care including assisting with patient interviews, maintenance of current medication lists, providing patient medication education, providing drug information to the healthcare team and patients. The pharmacist will practice with a high degree of autonomy, guided by IDS SOPs and quality assurance verification guidelines. This role is responsible for the daily supervision of staff assigned to medication preparation, dispensing, and operation of the IDS in accordance with all applicable rules and regulations. The director will serve as a direct supervisor to all site-specific pharmacy team members including other pharmacists and pharmacy technicians.
The annual base salary range for this role is $180,000 - $200,000 plus a significant annual bonus. Base pay may vary depending on multiple individualized factors including relevant and overall experience, job-related knowledge and skills.
Location: 450 Lakeville Road Entrance A New Hyde Park, New York 11042
Work Schedule: On-Site, 8am-5pm (flexibility in hours required), Monday-Friday
Essential Responsibilities
Required Education and Experience:
Preferred Education and Experience:
Physical & Travel Requirements:
Best-in-Class Benefits and Perks
We value our employees’ time and efforts. Our commitment to your success is enhanced by a competitive compensation, depending on experience, and an extensive benefits package including:
More about The START Center for Cancer Research
Deeply rooted in community oncology centers globally, The START Center for Cancer Research provides access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents. START clinical trial sites have conducted more than a thousand early-phase clinical trials, including for 43 therapies that were approved by the FDA. START represents the world’s largest roster of Principal Investigators (PIs) across its eight clinical trial sites. Committed to accelerating passage from trials to treatments, START delivers hope to patients, families, and physicians around the world.
Learn more at STARTresearch.com.
Ready to be part of a team changing the future of cancer treatment?
Join us in our mission to conquer cancer, one clinical trial at a time. Your expertise and dedication can help us bring hope and healing to patients worldwide. Please submit your application online.
We are an equal opportunity employer that welcomes and encourages diversity in the workplace. We do not discriminate on the basis of race, color, religion, marital status, age, national origin, ancestry, physical or mental disability, medical condition, pregnancy, genetic information, gender, sexual orientation, gender identity or expression, veteran status, or any other status protected under federal, state, or local law.
Phase 1 cancer trials with genomic profiling
START Center for Cancer Research runs Phase 1 clinical trials for novel anti-cancer therapies through a network of research sites in the United States, Spain, Portugal, and Ireland. It connects patients with early-stage trials, supported by genetic tumor profiling, multi-disciplinary care, and state-of-the-art treatment technology, to test new drugs before they reach broader use. The center distinguishes itself by its large, community-based trial network with 40+ principal investigators and a track record of conducting over 1,500 early-phase trials, including 50 therapies that later gained FDA/EMA approval. Its goal is to speed the translation of clinical research into available treatments and to expand access to innovative options for patients and physicians worldwide.
Explore more opportunities at START Center for Cancer Research